How many drugs treat Neonatal meningitis?

Drug Landscape tracks 10 marketed treatments for Neonatal meningitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/neonatal-meningitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Neonatal meningitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neonatal meningitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Neonatal meningitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Fortaz	CEFTAZIDIME	Pai Holdings Pharm	ceftazidime		1985-01-01
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial		1981-01-01
Claforan	CEFOTAXIME	Sterimax	Cephalosporin Antibacterial		1981-01-01
Vantobra	Tobramycin Sulfate	Pfizer	tobramycin	Taste receptor type 2 member 20	1974-01-01
Gentamicin	Gentamicin Sulfate	Merck & Co.	gentamicin	Dihydrofolate reductase	1970-01-01
Garamycin	GENTAMICIN	Merck & Co.	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 5	1970-01-01
Penicillin G Potassium In Plastic Container	Benzylpenicillin	Pfizer	Penicillin-class Antibacterial		1947-01-01
Ceftazidim	Ceftazidim	Tel-Aviv Sourasky Medical Center		Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI
Tobi	tobramycin	Novartis		Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)
penicillin	penicillin	Karlstad University		Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Merck & Co. · 2 drugs in Neonatal meningitis
Pai Holdings Pharm · 2 drugs in Neonatal meningitis
Pfizer · 2 drugs in Neonatal meningitis
Novartis · 1 drug in Neonatal meningitis
Sterimax · 1 drug in Neonatal meningitis
Tel-Aviv Sourasky Medical Center · 1 drug in Neonatal meningitis
· 1 drug in Neonatal meningitis
University Hospital, Lille · 1 drug in Neonatal meningitis
Bristol-Myers Squibb · 1 drug in Neonatal meningitis
Karlstad University · 1 drug in Neonatal meningitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Neonatal meningitis:

Cite this brief

Drug Landscape (2026). Neonatal meningitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/neonatal-meningitis. Accessed 2026-06-10.

Neonatal meningitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing